Interestingly, preclinical work suggested that selective B-RAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function, providing a rational for the combination of B-RAF inhibitors (e.g., vemurafenib or dabrafenib) with stimulatory immune agents (e.g., ipilimumab or PD-1/PD-L1) [92]. This evidence concerns the gene CD274 and melanoma.